Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

@inproceedings{Sedegah2011Adenovirus5P,
  title={Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults},
  author={Martha Sedegah and Cindy L. Tamminga and Shannon McGrath and Brent House and Harini D Ganeshan and Jennylynn Lejano and Esteban N. Abot and Glenna J. Banania and Renato Sayo and Fouzia Farooq and Maria Belmonte and Nalini Manohar and Nancy O. Richie and Chloe L Wood and Carole A. Long and David P Regis and Francis T. Williams and Meng Shi and I Chuan Chuang and Michele Spring and Judith E. Epstein and Jose Mendoza-Silveiras and Keith Limbach and Noelle B. Patterson and Joseph T. Bruder and Denise L. Doolan and C. Richter King and Lorraine A. Soisson and Carter Diggs and Daniel J. Carucci and Sheetij Dutta and Michael R Hollingdale and Christian F. Ockenhouse and Thomas L. Richie},
  booktitle={PloS one},
  year={2011}
}
BACKGROUND Models of immunity to malaria indicate the importance of CD8+ T cell responses for targeting intrahepatic stages and antibodies for targeting sporozoite and blood stages. We designed a multistage adenovirus 5 (Ad5)-vectored Plasmodium falciparum malaria vaccine, aiming to induce both types of responses in humans, that was tested for safety and immunogenicity in a Phase 1 dose escalation trial in Ad5-seronegative volunteers. METHODOLOGY/PRINCIPAL FINDINGS The NMRC-M3V-Ad-PfCA… CONTINUE READING
30 Extracted Citations
88 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 30 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 88 references

Similar Papers

Loading similar papers…